A study published in the Current Medical Research and Opinion journal assessed the outcomes of canagliflozin therapy in specific type 2 diabetic patient sub groups (patients aged ≥ 65 years, African American race, canagliflozin dose increase, initiating canagliflozin in endocrinology setting, and initiating canagliflozin in primary care setting). The study cohort involved 1,259 patients (mean age: 56.7 years; females: 51.2%; White: 70.4%). Among patients with a baseline glycated hemoglobin (HbA1c) ≥ 7%, 16.1% had an HbA1c < 7% 3 months following initiation of canagliflozin. The mean HbA1c value decreased from 8.8% to 8.1%. Among patients with a baseline systolic blood pressure (BP) ≥ 140 mmHg or diastolic BP ≥ 90 mmHg, 59.3% patients achieved a systolic BP < 140 mmHg and 77.3% a diastolic BP < 90 mmHg after 3 months. The proportion of patients with a weight loss from baseline ≥ 5% increased from 17% to 31.1% at 3 months and 12 months. The trends were consistent for all subgroups. Thus, it was suggested that canagliflozin can effectively improve HbA1c, BP, and weight in patients with type 2 diabetes mellitus.